On October 24, 2018, President Trump signed into law the SUPPORT for Patients and Communities Act, or the SUPPORT Act, to help address the opioid crisis. Over the past year, CMS has worked hard to implement certain provisions of the SUPPORT Act, and we’d like to share some of the milestones we have reached. We awarded nearly $48.5 million dollars to 15 states to help them plan demonstrations to increase the capacity of Medicaid providers to deliver substance use disorder treatment and recovery services. And, we’ve issued guidance that allows eligible pregnant and postpartum women to receive additional treatment outside of an institution for mental disease (IMD) while residing in an IMD facility. Furthermore, we’ve clarified treatment options for infants with Neonatal Abstinence Syndrome (NAS) that may be covered under Medicaid. CMS also expanded access to telehealth services for the treatment of Medicare beneficiaries with substance use disorder and co-occurring mental health conditions. And today, for the first time, we published a data book containing nationwide Medicaid data on substance use disorder prevalence and treatment. CMS SUPPORT Act endeavors are a key part of our three-pronged strategy to reduce opioid misuse through prevention, treatment and leveraging data to better target our efforts. While we have made great strides in implementing the SUPPORT Act, CMS is determined to continue executing the vision laid out by the Trump Administration in the years to come. For more information about CMS SUPPORT act endeavors and our strategy to combat the opioid epidemic, please visit cms.gov.